The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
CP-31398 Restores DNA-binding Activity to Mutant p53 in Vitro but Does Not Affect p53 Homologs p63 and p73
Abstract
The p53 protein plays a major role in the maintenance of genome stability in mammalian cells. Mutations of p53 occur in over 50% of all cancers and are indicative of highly aggressive cancers that are hard to treat. Recently, there has been a high degree of interest in therapeutic approaches to restore growth suppression functions to mutant p53. Several compounds have been reported to restore wild type function to mutant p53. One such compound, CP-31398, has been shown effective in vivo, but questions have arisen to whether it actually affects p53. Here we show that mutant p53, isolated from cells treated with CP-31398, is capable of binding to p53 response elements in vitro. We also show the compound restores DNA-binding activity to mutant p53 in cells as determined by a chromatin immunoprecipitation assay. In addition, using purified p53 core domain from two different hotspot mutants (R273H and R249S), we show that CP-31398 can restore DNA-binding activity in a dose-dependent manner. Using a quantitative DNA binding assay, we also show that CP-31398 increases significantly the amount of mutant p53 that binds to cognate DNA (B(max)) and its affinity (K(d)) for DNA. The compound, however, does not affect the affinity (K(d) value) of wild type p53 for DNA and only increases B(max) slightly. In a similar assay PRIMA1 does not have any effect on p53 core DNA-binding activity. We also show that CP-31398 had no effect on the DNA-binding activity of p53 homologs p63 and p73.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“One study revealed that CP31398 could facilitate the binding of mutant p53 to p53 response elements in vivo and restore the DNA-binding activity of mutant p53 in vitro.”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [318]
In the citing paper
“Moreover, CP31398 has no influence on the DNA-binding activity of p53 homologs (p63 and p73).318”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [318]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,551
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067
CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death
Wischhusen, J., Naumann, U., Ohgaki, H., Rastinejad, F., & Weller, M. (2003) · Oncogene · doi:10.1038/sj.onc.1207198 · Cited by 158
Research works printed but not linked: 34
- Bernard, 2003, Human Mutat., 2, 182, 10.1002/humu.10172 · DOI · Paper page
- Lane, 2003, Drug Discov. Today, 8, 347, 10.1016/S1359-6446(03)02669-2 · DOI
- Vousden, 2000, Cell, 103, 691, 10.1016/S0092-8674(00)00171-9 · DOI · Paper page
- Willis, 2002, Curr. Mol. Med., 2, 329, 10.2174/1566524023362474 · DOI
- Bullock, 2001, Nat. Rev. Cancer, 1, 68, 10.1038/35094077 · DOI · Paper page
- Wong, 1999, Proc. Nat. Acad. Sci U. S. A., 96, 8348, 10.1073/pnas.96.15.8348 · DOI
- Bullock, 1997, Proc. Nat. Acad. Sci. U. S. A., 94, 14338, 10.1073/pnas.94.26.14338 · DOI · Paper page
- Bullock, 2000, Oncogene, 19, 1245, 10.1038/sj.onc.1203434 · DOI · Paper page
- Nicholls, 2002, J. Biol. Chem., 277, 12937, 10.1074/jbc.M108815200 · DOI
- Mihara, 2003, Mol. Cell, 11, 577, 10.1016/S1097-2765(03)00050-9 · DOI · Paper page
- Abarzua, 1996, Oncogene, 13, 2477
- Abarzua, 1995, Cancer Res., 55, 3490
- Halazonetis, 1993, EMBO J., 12, 1021, 10.1002/j.1460-2075.1993.tb05743.x · DOI · Paper page
- Wieczorek, 1996, Nat. Med., 2, 1143, 10.1038/nm1096-1143 · DOI
- Selinova, 1999, Mol. Cell Biol., 19, 3395, 10.1128/MCB.19.5.3395 · DOI · Paper page
- Peng, 2003, Oncogene, 22, 4478, 10.1038/sj.onc.1206777 · DOI
- Foster, 1999, Science, 286, 2507, 10.1126/science.286.5449.2507 · DOI · Paper page
- Friedler, 2002, Proc. Nat. Acad. Sci. U. S. A., 99, 937, 10.1073/pnas.241629998 · DOI · Paper page
- Freidler, 2003, J. Biol. Chem., 278, 24108, 10.1074/jbc.M302458200 · DOI · Paper page
- Issaeva, 2003, Proc. Nat. Acad. Sci. U. S. A., 100, 13303, 10.1073/pnas.1835733100 · DOI · Paper page
- Luu, 2002, Exp. Cell Res., 276, 214, 10.1006/excr.2002.5526 · DOI
- Wang, 2003, Mol. Cell Biol., 23, 2171, 10.1128/MCB.23.6.2171-2181.2003 · DOI · Paper page
- Takimoto, 2002, Cancer Biol. Ther., 1, 47, 10.4161/cbt.1.1.41 · DOI
- Rippin, 2002, Oncogene, 21, 2119, 10.1038/sj.onc.1205362 · DOI · Paper page
- Frank, 2001, Genes Dev., 15, 2069, 10.1101/gad.906601 · DOI · Paper page
- Dignam, 1983, Nucleic Acids Res., 11, 1474, 10.1093/nar/11.5.1475 · DOI · Paper page
- Klein, 2001, J. Biol. Chem., 276, 37390, 10.1074/jbc.M103801200 · DOI
- Kaeser, 2002, Proc. Nat. Acad. Sci. U. S. A., 99, 95, 10.1073/pnas.012283399 · DOI · Paper page
- Friedler, 2004, J. Mol. Biol., 336, 187, 10.1016/j.jmb.2003.12.005 · DOI · Paper page
- Chipuk, 2003, Cancer Cell, 4, 371, 10.1016/S1535-6108(03)00272-1 · DOI · Paper page
- Dumont, 2003, Nat. Genet., 33, 357, 10.1038/ng1093 · DOI · Paper page
- Brachmann, 1998, EMBO J., 17, 1847, 10.1093/emboj/17.7.1847 · DOI · Paper page
- Nikolova, 2000, EMBO J., 19, 370, 10.1093/emboj/19.3.370 · DOI · Paper page
- Joerger, 2004, J. Biol. Chem., 279, 1291, 10.1074/jbc.M309732200 · DOI · Paper page
Cited by
Urothelial tumorigenesis: a tale of divergent pathways
Wu, X.-R. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1697 · Cited by 692
Mitra, A. P., Datar, R. H., & Cote, R. J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2073 · Cited by 284
Mutant p53 protein localized in the cytoplasm inhibits autophagy
Morselli, E., Tasdemir, E., Chiara Maiuri, M., Galluzzi, L., Kepp, O., Criollo, A., Vicencio, J. M., Soussi, T., & Kroemer, G. (2008) · Cell Cycle · doi:10.4161/cc.7.19.6751 · Cited by 277
Translational approaches targeting the p53 pathway for anti‐cancer therapy
Essmann, F., & Schulze‐Osthoff, K. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01570.x · Cited by 77
“By the use of recombinantly expressed DBD from the R273H p53 mutant in a DNA-binding assay, the piperazinylquinazoline SCH529074 (CAS 922150-11-6) was found to enhance DNA binding activity of mutant p53 (Demma et al., 2004).”
BackgroundMethodp53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 30
Metadata
- Authors
- Demma, M. J., Wong, S., Maxwell, E., & Dasmahapatra, B.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2004-10
- Volume
- 279
- Issue
- 44
- Pages
- 45887-45896
- ISSN
- 0021-9258
- Cited by
- 58
- References
- 3
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 5832 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.